Chemotherapy-induced thrombocytopenia remains one of the more frustrating complications in oncology: common, clinically significant, and still without any FDA-approved therapies. Dr. Al-Samkari’s work has helped reshape how clinicians think about diagnosing, risk-stratifying, and managing this condition.